The Effect of Sacubitril/Valsartan in a Dialysis Patient with Severe Heart Failure*
The Effect of Sacubitril/Valsartan in a Dialysis Patient with Severe Heart Failure*作者机构：The Nephrology Centre Department of the First Affiliated Hospital of Zhengzhou Zhengzhou China Nephrology Institute of Zhengzhou University Zhengzhou China
出 版 物：《Case Reports in Clinical Medicine》 (临床医学病理报告（英文）)
年 卷 期：2021年第10卷第7期
页 面：197-202页
学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学]
主 题：End Stage Renal Disease Sacubitril/Valsartan Hemodialysis Heart Failure Reduced Ejection Fraction
摘 要：Heart failure (HF) is a major comorbidity in patients with end-stage renal disease (ESRD). The pathogenesis of HF in patients on renal replacement therapy represents the confluence of several traditional and nontraditional vascular risk factors, unique to the milieu of chronic kidney disease and the dialysis modality [1]. The purpose of this report is to describe the efficacy and safety of sacubitril/valsartan for an ESRD patient on hemodialysis therapy conmbined with heart failure with reduced ejection fraction (HFrEF). A 35-year-old woman was undergoing hemodialysis due to ESRD and suffering from heart failure with reduced ejection fraction. Because of worsening heart failure and hypertension, she was prescribed with sacubitril/valsartan at a dose of 50 mg twice a day, spironolactone at a dose of 20 mg three times a day and metoprolol at a dose of 23.75 mg once daily. There was a symptomatic improvement with the heart failure and reduction in NT-proBNP level, accompanied by a decrease of blood pressure after using sacubitric/valsartan. In conclusion, it is safe and effective to take sacubitril/valsartan in this hemodialysis patient with severe heart failure.
维普期刊数据库